TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30045355
Drug: Intranasal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal Fentanyl (1.5 μg/kg)
Study: 25913538
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment as usual
Study: 24282229
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (40 mg, 3 times per day)
Study: 8385741
Drug: Placebo (identical-appearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-appearing tablets)
Study: 15197285
Drug: Enhanced psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced psychosocial treatment (comprehensive intervention with counseling, support, and consultation)
Study: 15197285
Drug: Enhanced psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced psychosocial treatment
Study: 11773290
Drug: Systemic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic adjuvant therapy (including chemotherapy and tamoxifen)
Study: 2657424
Drug: Intrathecal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal infusion of baclofen
Study: 25790022
Drug: EPA/DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA supplementation (650 mg of eicosapentaenoic acid and docosahexaenoic acid)
Study: 25790022
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g of margarine daily without EPA/DHA)
Study: 18499184
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (200 U intradetrusor injection)
Study: 10966968
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug administration
Study: 7825505
Drug: 0.3% S-1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% S-1033 solution
Study: 7825505
Drug: 0.4% S-1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% S-1033 solution
Study: 7825505
Drug: 0.3% S-1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% S-1033 solution (multiple-dose study)
Study: 7825505
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution (control)
Study: 29270836
Drug: MCP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP block (20 ml of ropivacaine 0.2%)
Study: 29270836
Drug: ISP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISP block (20 ml of ropivacaine 0.2%)
Study: 26284410
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg intravenously before anesthetic induction)
Study: 18484560
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (n=16)
Study: 17699258
Drug: Low-dose RATG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart)
Study: 17699258
Drug: Standard-dose RATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose RATG (2 mg/kg per d)
Study: 9099188
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram 1 alpha (OH)D3 daily + 300 mg elemental calcium
Study: 9099188
Drug: Inactive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo + 300 mg elemental calcium
Study: 8232358
Drug: Milacemide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide at a starting dose of 2,400 mg/day, increased to a maximum of 4,800 mg/day
Study: 3552455
Drug: Lignocaine (5%)
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine (5%) spray
Study: 3552455
Drug: Cinchocaine (2%)
Normalized name: cinchocaine
DrugBank: Cinchocaine (DB00527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cinchocaine (2%) spray
Study: 3552455
Drug: Water-only placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-only placebo spray
Study: 31209271
Drug: Starved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starved treatment (no food)
Study: 31209271
Drug: Fed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed treatment (ad libitum access to food)
Study: 25071343
Drug: Telbivudine (LDT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (LDT, 600 mg/d)
Study: 25071343
Drug: Lamivudine (LAM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (LAM, 100 mg/d)
Study: 24304478
Drug: Self-weighing twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-weighing twice a day with daily target setting and feedback (group 2)
Study: 20679147
Drug: Fortified drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified drinking water with 7.5 mg of elemental iron per liter (group B)
Study: 20679147
Drug: Fortified drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified drinking water with 10 mg of elemental iron per liter (group C)
Study: 20679147
Drug: Fortified drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified drinking water with 5 mg of elemental iron per liter (group A)
Study: 18806533
Drug: Ibandronate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (6 mg infusions administered on each of 3 days)
Study: 12689976
Drug: Counselling on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling on physical activity (green prescription programme)
Study: 10569217
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (PerMamma Abbott) providing 20mg zinc sulfate, 2mg copper sulfate, and 116 microg potassium iodide.
Study: 10569217
Drug: Traditional Italian
Normalized name: ALLERGENIC EXTRACT, ITALIAN RYEGRASS POLLEN
DrugBank: Lolium perenne subsp. multiflorum pollen (DB10964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Italian diet without vitamin and mineral supplements.
Study: 9972143
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (LDD)
Study: 1860094
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg once daily (increased to 20 mg if needed)
Study: 17619207
Drug: Analgesics (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics (50 mg pethidine and 10 mg diazepam)
Study: 15899018
Drug: Transmandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transmandibular implant-retained overdentures
Study: 15899018
Drug: Four endosseous
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four endosseous implants following augmentation of the mandible
Study: 15899018
Drug: Four short
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four short endosseous implants
Study: 15899018
Drug: Laboratory-assessed masticatory
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory-assessed masticatory function (before treatment)
Study: 9583839
Drug: Small supplement
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small supplement (0.93 micromol beta‐carotene/d, first 60 days)
Study: 9583839
Drug: Small supplement
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small supplement (0.93 micromol beta‐carotene/d, days 61-120)
Study: 9583839
Drug: Larger mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger mixed carotenoid supplement (6.16 micromol beta‐carotene/d, days 101-120)
Study: 29745298
Drug: Experimental protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental protocol using TICCS for treatment guidance
Study: 24314930
Drug: Tacrolimus Medis
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus Medis 5 mg
Study: 24314930
Drug: Prograf® 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf® 5 mg
Study: 21806769
Drug: Valsartan/Amlodipine/HCTZ 160/5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine/HCTZ 160/5/25 mg
Study: 21806769
Drug: Losartan/HCTZ 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ 100/25 mg
Study: 21806769
Drug: Valsartan/Amlodipine/HCTZ 320/10/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine/HCTZ 320/10/25 mg (after titration)
Study: 16930934
Drug: L-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine treatment for 6 months
Study: 31300595
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg)
Study: 8496313
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA; 20 mg/day) with GnRH analog (leuprolide acetate; 1 mg/day, sc)
Study: 31603012
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT4): oral dexamethasone 40 mg for days 1-4, oral cyclosporine A 2–3 mg/kg daily for 28 consecutive days, intravenous rituximab 100 mg for days 7, 14, 21, and 28
Study: 31603012
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT4)
Study: 30112726
Drug: DFN-11 (sumatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-11 (sumatriptan injection, 3 mg)
Study: 21144456
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with co-interventions (including NSAIDs or analgesics)
Study: 19195455
Drug: Darunavir (DRV/r)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir (DRV/r) 600/100 mg two times a day
Study: 16606546
Drug: Nebulized furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized furosemide (10 mg/m2) plus nebulized salbutamol (0.15 mg/kg)
Study: 16606546
Drug: Nebulized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized saline (placebo) plus nebulized salbutamol (0.15 mg/kg)
Study: 12846772
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of iron sucrose administered intravenously over two hours
Study: 12846772
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously over two hours
Study: 1451726
Drug: MK-571 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (75 mg)
Study: 1451726
Drug: MK-571 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (300 mg)
Study: 1451726
Drug: MK-571 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (600 mg)
Study: 1451726
Drug: MK-571 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (all doses)
Study: 2698566
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg
Study: 6391005
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg and Nifedipine 10 mg
Study: 28557857
Drug: 5-mg melatonin
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg melatonin supplement
Study: 27491280
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg alone
Study: 27491280
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg alone
Study: 27491280
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg plus Dapagliflozin 10 mg coadministered
Study: 22479985
Drug: Combined orthodontic/regenerative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orthodontic/regenerative therapy with immediate orthodontic tooth movement
Study: 22479985
Drug: Combined orthodontic/regenerative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orthodontic/regenerative therapy with delayed orthodontic tooth movement
Study: 22479985
Drug: Regenerative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative therapy alone (control group)
Study: 17609397
Drug: GHRP-2 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRP-2 (100 microg dose administered intravenously)
Study: 11892709
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of methylprednisoloneacetate and lidocaine (MP group)
Study: 10780243
Drug: Ethanol (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.2, 0.4 or 0.8 g/kg)
Study: 10780243
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25 or 0.5 mg)
Study: 6167117
Drug: Aspirin dipyridamole
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin dipyridamole combination
Study: 31810219
Drug: Rice with
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice with sugar solution preload (PSS+R)
Study: 29957283
Drug: Task-oriented daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented daily physical activity (DPA) assessed using interviewer-administered recall questionnaire (DPA-R) in Cohort 1
Study: 29957283
Drug: Task-oriented daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented daily physical activity (DPA) assessed using self-administered diary-format daily checklist (DPA-C) in Cohort 2
Study: 26874291
Drug: Exposure based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure based treatment
Study: 22760558
Drug: Almond-containing diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond-containing diet (42 g/d)
Study: 22760558
Drug: Almond-containing diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond-containing diet (84 g/d)
Study: 22760558
Drug: Controlled diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled diet (0 g/d)
Study: 19896213
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination treatment
Study: 15277171
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling to increase intake through diet and high-energy supplements
Study: 7826222
Drug: Ozagrel (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozagrel (400 mg/day) for 4 weeks, then DSCG (8 mg/day) for 4 weeks
Study: 7826222
Drug: DSCG (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSCG (8 mg/day) for 4 weeks, then Ozagrel (400 mg/day) for 4 weeks
Study: 22289281
Drug: Esmolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (50 μg/kg/min)
Study: 30129080
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 30 treatments of 100% oxygen at 2.4 ATA for 80 minutes
Study: 30129080
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment - 30 'sham' treatments, initially pressurized to 1.2 ATA, then cycled between 1.05–1.2 ATA for eight minutes before settling at 1.05 ATA
Study: 25592656
Drug: Levofloxacin inhalation
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin inhalation solution (APT-1026)
Study: 24018268
Drug: Social Cognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Cognition and Interaction Training (SCIT) plus treatment-as-usual
Study: 24018268
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group (treatment-as-usual only)
Study: 21788905
Drug: Omocianine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omocianine (0.1 mg/kg)
Study: 21788905
Drug: Omocianine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omocianine (all dose groups)
Study: 7484983
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (diphenhydramine, 12.5 mg)
Study: 7484983
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with detectable blood levels
Study: 7484983
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with no detectable blood levels
Study: 8648369
Drug: Epirubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 60 mg/m2
Study: 2265137
Drug: Epirubicin 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 45 mg/m2 and Vindesine 3 mg/m2 on days 1 and 8 every 4 weeks
Study: 538812
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of long-acting penicillin (Triplopen)
Study: 30204244
Drug: Tick‐E‐Vac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tick‐E‐Vac vaccine
Study: 30204244
Drug: EnceVir vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EnceVir vaccine
Study: 30204244
Drug: Tick‐E‐Vac and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tick‐E‐Vac and EnceVir vaccines
Study: 28328712
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (25 g)
Study: 28328712
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (25 g)
Study: 24383406
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Treatment of Insomnia (BBTI)
Study: 17302587
Drug: EC‐MPS 1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 1080 mg bid
Study: 17302587
Drug: MMF 1500
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1500 mg bid
Study: 11256540
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus 25 mg i.v. of canrenoate (1 mg/hour for the first 72 hours and then orally 25 mg/day)
Study: 8032582
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg and codeine 30 mg in one combination tablet
Study: 8032582
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg and codeine 60 mg in one combination tablet
Study: 8032582
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg and codeine 30 mg in two separate tablets
Study: 8032582
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg and codeine 60 mg in two separate tablets
Study: 2600323
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg every 12 hours for seven doses
Study: 30804129
Drug: Gefitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib at 250 mg/day
Study: 30804129
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus bevacizumab at 15 mg/kg every 3 weeks
Study: 26422724
Drug: Cigarettes containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes containing 2.4 mg of nicotine per gram of tobacco
Study: 26422724
Drug: Cigarettes containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes containing 1.3 mg of nicotine per gram of tobacco
Study: 26422724
Drug: Cigarettes containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes containing 0.4 mg of nicotine per gram of tobacco
Study: 26422724
Drug: Cigarettes containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes containing 15.8 mg of nicotine per gram of tobacco
Study: 26422724
Drug: Cigarettes containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes containing 5.2 mg of nicotine per gram of tobacco
Study: 17519902
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IV‐MO)
Study: 15771319
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg once daily
Study: 12714828
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (60-U/kg bolus and 12-U/kg/h infusion for 72 hours)
Study: 12714828
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (not specified dosage)
Study: 2659136
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose polyoestradiol phosphate (PEP) 160 mg
Study: 2659136
Drug: Daily low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low dose acetosalicylic acid (ASA) 75 mg
Study: 28833832
Drug: EtG-based contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtG-based contingency management (CM) intervention for alcohol abstinence and addiction treatment attendance for 12 weeks
Study: 21228137
Drug: Intranasal measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal measles vaccine (Moraten)
Study: 21228137
Drug: Subcutaneous measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous measles vaccine (Moraten)
Study: 16723785
Drug: Pilsicainide (Pil)
Normalized name: Pilsicainide
DrugBank: Pilsicainide (DB12712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide (Pil) 150 mg/day
Study: 16723785
Drug: Cibenzoline (Cib)
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (Cib) 300 mg/day
Study: 11421998
Drug: Domperidone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (1 mg kg‐1)